About HLA class II histocompatibility antigen, DP beta 1 chain
HLA class II histocompatibility antigen, DP beta 1 chain (HLA-DPB1) is a protein
from Homo sapiens identified by UniProt accession
P04440, 258 residues long.
MolForge cross-references it against 0 known binders and
249 disease associations.
Target properties
| Protein name | HLA class II histocompatibility antigen, DP beta 1 chain |
|---|
| UniProt accession | P04440 |
|---|
| Gene | HLA-DPB1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 258 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (249)
Diseases linked to this target (Open Targets).
- hepatitis B virus infection · score 0.33
- chronic hepatitis B virus infection · score 0.31
- response to vaccine · score 0.27
- allergic rhinitis · score 0.26
- Eczematoid dermatitis · score 0.26
- dermatomyositis · score 0.24
- hypothyroidism · score 0.23
- Granulomatosis with Polyangiitis · score 0.23
- albumin:globulin ratio measurement · score 0.22
- susceptibility to hepatitis B infection measurement · score 0.21
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P04440-F1 | alphafold | PREDICTED | 87.39 | — |
Amino-acid sequence (258 residues)
MMVLQVSAAP RTVALTALLM VLLTSVVQGR ATPENYLFQG RQECYAFNGT QRFLERYIYN REEFARFDSD VGEFRAVTEL GRPAAEYWNS QKDILEEKRA VPDRMCRHNY ELGGPMTLQR RVQPRVNVSP SKKGPLQHHN LLVCHVTDFY PGSIQVRWFL NGQEETAGVV STNLIRNGDW TFQILVMLEM TPQQGDVYTC QVEHTSLDSP VTVEWKAQSD SARSKTLTGA GGFVLGLIIC GVGIFMHRRS KKVQRGSA
Explore HLA class II histocompatibility antigen, DP beta 1 chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets